GlassScriptPhysician profile
Robert Dajac
NPI 1104841915
$4,180.34
in general payments reported to CMS, 2019-2025
23 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $809 · 2021: $929 · 2022: $700 · 2023: $260 · 2024: $230 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $723.83 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $534.22 | 2019-2024 | Airsupra, Farxiga |
| Pfizer INC. | $499.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $475.52 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $473.01 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.85 | 2021-2023 | |
| Lilly USA, LLC | $218.29 | 2020-2023 | Mounjaro |
| Novo Nordisk INC | $189.77 | 2019-2023 | Rybelsus, Ozempic |
| Stryker Corporation | $173.77 | 2025 | Mako |
| Sunovion Pharmaceuticals INC. | $142.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $116.51 | 2019-2022 | |
| Amarin Pharma, INC. | $84.62 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $79.49 | 2023-2025 | Gemtesa |
| Amgen INC. | $39.50 | 2022-2023 | Repatha |
| Exact Sciences Corporation | $32.71 | 2024 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.08 | 2019-2025 | |
| Abbott Laboratories | $28.94 | 2023 | Proclaim |
| Ethicon US, LLC | $28.06 | 2024 | Harmonic, Stratafix, Vistaseal |
| Horizon Therapeutics Plc | $23.08 | 2022 | |
| Merck Sharp & Dohme LLC | $19.87 | 2020 | |
| Dexcom, INC. | $17.54 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.17 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dajac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.